Vol 21 No 3 (2015)

Vol 21 No 3 (2015)

Published July 1, 2015

Commentary

Menghis Bairu
Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs
Requires Subscription or Fee PDF
Peter J. Pitts
The Globetrotting Regulator
Requires Subscription or Fee PDF
Peter Pitts
FDA: Is Off-Label on the Table?
Requires Subscription or Fee PDF
Henry I Miller, Graham Brookes
A ‘Genetically Engineered’ Label: Way More Expensive Than You Think
Requires Subscription or Fee PDF

Articles

Clifford S Mintz, Evan Nison, AJ Fabrizio
Cannabis-Derived Pharmaceuticals
Requires Subscription or Fee PDF
Kenneth Fernald, Ruud Hoeben, Eric Claassen
Venture Capitalists as gatekeepers for Biotechnological Innovation
Requires Subscription or Fee PDF

From the Boardroom

Ian C. Clift
BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision
Requires Subscription or Fee PDF

Legal and Regulatory Updates

Henry Elliott
EU Legal & Regulatory Update – May 2015
Requires Subscription or Fee PDF

Conference Report

Vasu Pestonjamasp
Innovation Landscape, Deal-making Strategies and Success Stories
Requires Subscription or Fee PDF